Qu Biologics announces phase 1/2 trial of treatment for Crohn’s disease

Qu Biologics is launching a phase 1/2 clinical trial to evaluate the potential clinical response and disease remission among participants with Crohn’s disease treated with Qu Biologics site specific immunomodulators (SSIs) treatment candidate, QBECO. SSI is a class of immunotherapies that aim to restore balance to the body’s natural defense system by potentially “rebooting” the affected organ’s innate immune response.

Crohn’s disease is a type of inflammatory bowel disease that affects more than 100,000 Canadians causing a range of debilitating symptoms including abdominal pain, diarrhea, vomiting and weight loss. Crohn’s disease is one of a number of autoimmune diseases and cancers that are marked by chronic inflammation within a specific organ or tissue.

Health Canada has determined that outcomes from a compassionate use program with a small number of Crohn’s patients support further study in controlled clinical trials of QBECO.

Qu Biologics’ Phase 1/2 clinical trial will recruit 60 adults with active, uncontrolled, moderate to severe Crohn’s Disease and evaluate the potential clinical response and disease remission among participants treated with QBECO.

The main purpose of this study will be to test whether this investigational treatment is safe and potentially effective for the treatment of Crohn’s disease. Results could be expected as early as the second quarter of 2014.

Qu Biologics is currently recruiting participants for this study. To learn more about eligibility requirements please visit: www.qucrohnstrial.com.